19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting the mRNA-decapping enzyme DCPS could help treat AML. Screening of a CRISPR single-guide RNA (sgRNA) library targeting protein-coding genes and miRNAs in two...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Repligen, Pfizer deal

Repligen received a $1 million milestone payment from Pfizer under a 2012 deal granting the pharma exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program. The milestone, which is the first...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

Repligen, Pfizer deal

Repligen granted Pfizer exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program, which includes lead candidate RG3039 and undisclosed backup SMA compounds. Repligen will receive $5 million up front and is...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $0.80 to $24.91 Christmas week after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Juxtapid was approved with a REMS and a boxed...
00:51 , Jan 4, 2013 |  BC Extra  |  Company News

Repligen licenses SMA program to Pfizer

Repligen Corp. (NASDAQ:RGEN) granted Pfizer Inc. (NYSE:PFE) exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program, which includes lead candidate RG3039 and undisclosed backup SMA compounds. Repligen will receive $5 million...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

RG3039: Phase Ib started

Repligen began a double-blind, placebo-controlled, U.S. Phase Ib trial evaluating multiple ascending-doses of oral RG3039 for 28 days in 32 healthy adult volunteers. RG3039 has Orphan Drug designation in the U.S. and EU and Fast...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Repligen diagnostic, neurology news

Repligen disclosed in its 2Q12 earnings that it will now seek to partner its therapeutic product pipeline to focus resources on expanding its bioprocessing business, which recorded 2Q12 revenue of $11.7 million. The company's pipeline...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Arte, ProJect Pharmaceutics deal

Japanese pharmaceutical glass packaging systems manufacturer Arte partnered with ProJect, a German developer of filling and freeze-drying processes, to develop a lyophilized dual chamber prefillable syringe (Lyo- DCPS ) for use with freeze-dried pharmaceuticals. The...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

RG3039: Phase I data

A blinded, U.S. Phase I trial in 32 healthy volunteers showed that single ascending-doses of RG3039 were well tolerated with no serious adverse events reported. Repligen also said there was evidence that RG3039 led to...
08:00 , Dec 12, 2011 |  BioCentury  |  Product Development

Back for seconds

A second deal between Roche and PTC Therapeutics Inc. demonstrates both the pharma's increasing push into CNS diseases, and its confidence in PTC's small molecule approaches to modifying RNA biology. Last month, the partners announced...